Maninil 5 tabs 5mg #120

User manual for Maninil

Reed more and buy Maninil on this page

Maninil refers to hypoglycemic medicines of the oral form.

Composition, form of release

The medication is produced in the form of pink tablets having a flat-cylindrical shape, facet and risk on one side. Each tablet contains 3.5 mg of active compound in the form of glibenclamide.
As additional compounds, magnesium stearate, gimetellose, lactose monohydrate, crimson dye, colloidal silicon dioxide, potato starch are used.

Pharmacological properties

Hypoglycemic medication Maninil 3,5 belongs to the sulfonylurea group.
The main substance of the drug activates the production of insulin due to the connection with special receptors that are located on the walls of the cells of the pancreatic gland. Also, the drug enhances insulin susceptibility and strength of its connection with cells, increases insulin secretion, activates insulin action on glucose uptake in the liver and muscles, thus reducing the amount of glucose in the blood.
The action of the drug is manifested in the second stage of insulin secretion. The drug inhibits the process of lipolysis in fatty tissues. Has a hypolipidemic effect, reduces thrombogenic characteristics in the blood.
Maninil 3,5 tablets are released in the form of a micronized form, which is a high-tech, determined by the shredded form of glibenclamide, which helps the medicine to be quickly and easily absorbed in the digestive tract. Since the highest amount of active compound is reached in the blood at the same time as the increase in the amount of glucose in the blood that occurs after ingestion, the effectiveness of the drug due to this is manifested gently and physiologically. The duration of hypoglycemic effect is from 20 to 24 hours.
The medicine is excreted by the kidneys and intestines.

Indications for use

The medication is prescribed for diabetes mellitus 2 types. The drug can be prescribed as a monotherapy, or as part of an integrated treatment with other hypoglycemic medications in oral form (not including clay and sulfonylurea derivatives).

Dosing regimen

The dosage of the medication is dependent on the age category of the patient, the complexity of the course of diabetes, the amount of glucose in the blood on an empty stomach and 2 hours after eating.
The initial dosage of Maninil 3,5 is 0.5-1 tablet once a day. If the desired effectiveness is not manifested in full, then the specialist can gradually increase the daily dosage, which stabilizes the carbohydrate metabolism. The dosage is increased at intervals of 2 to 7 days. The highest dosage per day is 3 tablets.

Overdose

If the drug is administered at a dosage exceeding the therapeutic limit, the following symptoms may appear: neurological changes, fear, tremor, skin moisture, drowsiness, hyperthermia, hypoglycemia, headache, anxiety, negative changes in coordination of movements, weakness, tachycardia, a feeling of hunger.
In the case of a slight overdose, the patient should take a small amount of sugar, food or a drink with the presence of sugar. If the patient has lost consciousness, then an intravenous injection with a solution of dextrose is made.

Drug Interactions

An increase in the hypoglycemic effect of the drug Maninil may be with concomitant administration of ACE inhibitors, other oral hypoglycemic drugs, NSAIDs, quinolone derivatives, clofibrate, disopyramide, antifungal drugs, MAO inhibitors, perhexylin, probenecid, sulfonamides and tritvaline.
Medications that acidify urine (calcium chloride or ammonium chloride) increase the activity of Maninil.
With the parallel administration of drugs such as barbiturates, diazoxide, nicotinates, phenothiazines, thiazide diuretics, acetazolamide, estrogens, and sympathomimetic drugs, the hypoglycemic effect of Maninil may decrease.
The simultaneous administration of H2-receptor antagonists can both increase and decrease the hypoglycemic effect of the drug Maninil.
In rare cases, the drug pentamidine may cause a significant decrease or increase in the amount of glucose in the blood.
The joint administration of the drug Maninil with coumarin derivatives may enhance or weaken the efficacy of the latter.
In addition to enhancing the hypoglycemic effect, beta-adrenoblockers, reserpine, guanetidine, clonidine and drugs with an effect on the central nervous system may mask manifestations of previous signs of hypoglycemia.

Lactation, pregnancy

Medication can not be administered to patients during breastfeeding and pregnancy.
In the case when pregnancy has come during therapy, the medicine is canceled.

Side effects

The purpose of the medication can provoke the following undesirable manifestations:
    The system of hematopoiesis: agranulocytosis, pancytopenia, erythropenia, thrombocytopenia;
    Bile ducts and liver: hepatitis, an increase in the activity of liver enzymes;
    Metabolism: weight gain, hypoglycemia (neurological disorders in the form of paralysis, paresis, speech and vision impairment, headache, anxiety, negative changes in coordination of movements, weakness, tachycardia, hunger, fear, tremor, skin moisture, drowsiness , hyperthermia);
    Immune system: allergic manifestations, which are accompanied by jaundice, fever, rash on the skin, proteinuria, arthralgia;
    Digestive system: the taste of metal in the mouth, abdominal pain, belching, nausea, diarrhea, vomiting, a feeling of heaviness in the abdomen;
    Other: hyponatremia, increased diuresis, proteinuria, negative changes in accommodation, visual impairment.
    High susceptibility to any component of the drug;
    The age is under 18 years;
    Pregnancy;
    Lactose intolerance;
    Leukopenia;
    Renal failure in severe stages;
    Diabetes mellitus 2 types;
    Lactation;
    Gastric paresis, obstruction in the intestine;
    Hepatic insufficiency in the severe stage;
    Ketoacidosis is a diabetic form, coma, precoma is diabetic.

Contraindications

DM of the first type, diabetic precoma, coma, ketoacidosis, hyperosmolar coma, extensive burns, traumas, leukopenia, infectious diseases, pregnancy, microangiopathy, hepatic, renal failure, intestinal obstruction.
Caution is prescribed for adrenal insufficiency, alcoholism, febrile syndrome, thyroid diseases.

special instructions

During the period of therapy, you should strictly follow all the recommendations of a specialist concerning the diet, and independently control the amount of glucose in the blood.
Long abstinence from eating, small intake of carbohydrates, high physical activity, vomiting or diarrhea are a risk of hypoglycemia.
Joint intake of medications that affect the central nervous system and lower blood pressure, can mask signs of hypoglycemia.
In elderly patients, the likelihood of hypoglycemia is much higher. In this regard, you should carefully select the dosage of the drug and constantly monitor the amount of glucose in the blood on an empty stomach and after eating.
Alcohol intake can trigger the appearance of hypoglycemia, and develop a sulfiramine-like reaction (headache, tachycardia, pain in the abdomen, nausea, dizziness, a feeling of heat on the skin of the face, vomiting). In this regard, you should not take alcohol during the period of therapy with Maninil.
With large injuries and surgical operations, infectious diseases with a febrile syndrome and significant burns, it may be necessary to cancel oral hypoglycemic drugs.
During therapy it is not recommended to stay in the sun for a long time.
Patients taking Maninil should be cautious when driving vehicles and when engaging in activities that require high attention and quick response.

Terms and conditions of storage

The medicament is stored at a temperature of not more than 30 g C in a place remote from small children. The medicine is allowed to be used within 3 years from the moment of its release.